Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Pharmaceutical sales up 2% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck

2Q Revenues: $9.8 billion (+1%)

2Q Earnings: $1.2 billion (+100%)

YTD Revenues: $19.2 billion (flat)

YTD Earnings: $2.3 billion (+42%)

Comments: Pharmaceutical sales were up 2% to $8.7 billion, with higher sales in oncology, hospital acute care, the cardiovascular franchise and vaccines. KEYTRUDA sales were $314 million in the quarter, up from $110 million 2Q15. CUBICIN sales were $357 million, up 22%. The company launched HCV drug ZEPATIER, which had sales of $112 million in the quarter. REMICADE sales were down 26% to $339 million, due to the impact of biosimilar competition. JANUVIA sales were $1.6 billion, up 2%. ZETIA/VYTORIN sales were $994 million, up 4%. GARDASIL sales were down 7% to $393 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters